secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2026-06-22T13:17:24+00:00
Accession:  0001193125-26-276845
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure
--------------------------------------------------------------------------------

- Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.
- Process aligns with planned completion of clinical work for NDA submission for crofelemer in rare intestinal failure diseases.
- Crofelemer reduced parenteral support by up to 37% in pediatric MVID/short bowel syndrome proof-of-concept trial.
- Third-party report estimates global nutritional support market for MVID at ~$1.1B in 2026, growing to ~$1.5B by 2033.
- CEO Lisa Conte to update on crofelemer program at Life Sciences Virtual Investor Forum on June 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/0001193125-26-276845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/d27128d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-276845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer